Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.
about
Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsClinical cardiac safety profile of nilotinib.Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcomeManaging chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Quality of life in chronic myeloid leukaemia patients after haematopoietic cell transplantation pretreated with second-generation tyrosine kinase inhibitors.Treatment recommendations for chronic myeloid leukemiaSerum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.A critical history of chromic myeloid leukemiaUnderstanding and Challenges in Taking Tyrosine Kinase Inhibitors among Malaysian Chronic Myeloid Leukemia Patients: A Qualitative Study
P2860
Q28078946-A2451681-EFB3-422B-B7FF-95DC34A00FE2Q36006389-C09B0607-9A41-4A37-86A9-7B0368009B63Q36059184-F0C1064E-AAED-45DF-884B-C16A00EF3E22Q36288815-8F49B1EA-9A56-49FC-9094-D3D5970A9905Q37026032-98183370-3517-41D0-83C3-3D252D1DA4D0Q37727668-BA3015A2-E2F5-42EB-A089-55AB0DD94E3AQ38181112-61EA54B3-696A-4570-B7CF-7B6DCFFC13B4Q41515301-2E9CB05A-61D6-43DC-933A-3F304A348218Q41877378-976E9BB8-F549-46BC-8414-F20E02D73C63Q42672759-13961FA3-20F9-404F-87DD-58A19D0FE673
P2860
Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Severe adverse events associat ...... n patients with comorbidities.
@en
Severe adverse events associat ...... n patients with comorbidities.
@nl
type
label
Severe adverse events associat ...... n patients with comorbidities.
@en
Severe adverse events associat ...... n patients with comorbidities.
@nl
prefLabel
Severe adverse events associat ...... n patients with comorbidities.
@en
Severe adverse events associat ...... n patients with comorbidities.
@nl
P2860
P1433
P1476
Severe adverse events associat ...... n patients with comorbidities.
@en
P2093
Peter Valent
P2860
P304
P356
10.3324/HAEMATOL.2011.052076
P577
2011-10-01T00:00:00Z